Last updated 2026-07-20
- Went public on TASE (BIOV), Mar 2006
- Raised $6.5M Follow-on PO led by Rosario Capital, Mar 2006
- Raised $1.1M Follow-on PO, May 2008
Total raised
$7.6M
Stage
Public
Founded
2000
Headcount
30
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
BioView develops, manufactures, and markets innovative automated cell imaging and analysis solutions for cytology, cytogenetic, pathology clinical and research laboratories worldwide. The company's technology provides automatic control of fully motorized fluorescent and bright-field microscopes fitted with high-resolution cameras, which automate the review, analysis, and reporting processes. BioView's solutions are used in cytogenetic, pathology, cytology, clinical, research, and tumor cell applications. The company is headquartered in Rehovot, Israel, and has a fully owned subsidiary in the United States responsible for sales and support in the Americas. Products are also internationally distributed by leading partners like Abbott Molecular Inc..
Funding history · 3 rounds · $7.6M total
2010-04
PIPE
Undisclosed
★ MRC Investments Ltd.
2008-05
Follow-on PO
$1.1M
2006-03
Follow-on PO
$6.5M
★ Rosario Capital★ Orbotech Ventures★ Gilbridge Holdings★ Altshuler Shaham Ltd.★ IBI Investment House Ltd.★ Marathon Venture Capital Fund★ Clal Finance Underwriting Ltd.
Headcount over time
From 31 (2018-11) to 36 (2025-12) · +5 (+16%) · 16 points · source: Finder history + radar grounding
Q&A
- What is BioView's primary focus?
- BioView develops, manufactures, and markets automated cell-imaging and analysis solutions for use in cytology, cytogenetic, pathology, clinical, and research laboratories.
- When was BioView founded?
- BioView was founded in August 1998.
- What is the status of BioView's DUET imaging and analysis platform?
- BioView's DUET imaging and analysis platform has received FDA clearance for several FISH applications for cancer detection and diagnosis and detection of genetic aberrations.
- What is BioView's current development focus?
- BioView is currently developing and plans to market a proprietary, self-developed test for noninvasive early detection of lung cancer, combining a biological test kit and its unique Target FISH application.
- What was BioView's most recent funding round?
- In April 2010, BioView completed a PIPE funding round with MRC Investments Ltd., raising $300,000.
- What was BioView's initial public offering?
- In March 2006, BioView completed a Public Offering, raising $6,300,000. The offering was joined by IBI Investment House Ltd. and Clal Finance Underwriting Ltd.
- What is the status of BioView's agreement with Abbott Molecular?
- In June 2026, BioView signed an annex to its agreement with Abbott Molecular, adding the Encore system and extending the agreement until June 2027.
- What was a significant recent development for BioView regarding its LiquidView activity?
- In January 2026, BioView announced a memorandum of understanding for the sale of its LiquidView activity to a NASDAQ company.
Team · 4
Opher Shapira
Founder · CEO
Yuval Harari
Founder · VP Product Development
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Technologies
Platforms & InterfacesSoftwareSimulation & Imaging
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesLife SciencesBiotechnology
Business model
B2B
Highlights
1 PatentsVerified
Tags
diagnosticsimagingmedical-technologiesmedical-equipmentcellslaboratoriesmobile-devicescancergeneticsnon-invasiveartificial-intelligenceoncologyurologyhospitalsoptronicshematologyhardwaremedical-devicessaas
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bioview.com/ |
|---|---|
| linkedin.com/company/80102 | |
| facebook.com/BioViewInc |
Identifiers & details
| Legal name | Bio-View Ltd. |
|---|---|
| Founded | 2000 |
| Employees (exact) | 30 |
| Offices | USA |
| Market cap | $7.2M |
| Status reason | Public on TASE on Jul, 2006 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2006-03 | TASE | BIOV | $6.3M |
Radar intelligence
Patents
| EPO | 9 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
GitHub
| Top repos | bioview-common |
|---|
Web history (Wayback)
| Domain | bioview.com |
|---|
Certificate / subdomain footprint
| Subdomains | 17 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512671371 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1998-08-18 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 2 |
| Registry events | 2 — charge (2) |
| Registered address | פקריס 3 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-07-27 | רישום שעבוד |
| 2025-07-24 | רישום שעבוד |